Breast Cancer Study - For adults whose breast cancer has spead to the brain


A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination With Trastuzumab and Vinorelbine in the Treatment of Progressive HER-2 Positive Breast Cancer Brain Metastases (LCCC 1025)


Dillon Patrick, M

UVa Health System, Cancer Center, Division of Hematology/Oncology seeks men and women over the age of 21 with stage IV HER2-positive breast cancer for a research study. The purpose of the study is to determine if an experimental medicine, called RAD001 (everolimus), can shrink breast cancer tumors that have spread to the brain when given with anti-cancer drugs, called trastuzumab and vinorelbine. All study patients will receive anti-cancer drugs trastuzumab and vinorelbine IV as standard of care. In addition, participants will get weekly experimental medicine, RAD001 by mouth daily. Study patients will have physician visits, blood draws, and imaging scans throughout the study. There will be at least 6 study visits over a 4 month period and one follow-up. * RAD001 will be provided free of charge. * Participant’s insurance company will be billed for some tests and procedures that are part of clinical care. * No compensation is provided for this study. Contact Information: For more information please contact: • Christina Taylor, RN • 434-243-0425 / • IRB-HSR #15842 Principal Investigator: Patrick Dillon, MD


Brain Cancer
Breast Cancer

Women's Health
Cancer (Oncology)


No Compensation

Christina Taylor